HHS Announces $100M Investment in Substance Use and Mental Health Treatment

U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced a $100 million investment to expand substance use disorder treatment, mental health services and housing-related supports under the administration’s Great American Recovery initiative.

The funding will launch the Safety Through Recovery, Engagement, and Evidence-based Treatment and Supports (STREETS) initiative, which will support targeted outreach, psychiatric care, medical stabilization, crisis intervention and connections to stable housing for individuals experiencing homelessness and substance use disorder.

HHS also announced a $10 million Assisted Outpatient Treatment (AOT) grant program to support adults who have difficulty engaging in traditional outpatient care. The program uses court-ordered, community-based treatment as an alternative to hospitalization, homelessness or involvement with the criminal justice system.

In addition, HHS announced changes allowing states and tribes to receive a 50% federal match to provide medications for opioid use disorder, buprenorphine, methadone and naltrexone, to parents whose children are at risk of entering foster care. The medications are approved by the U.S. Food and Drug Administration and are intended to support recovery and family stability.

Members with questions may contact Lenise Freeman at the MHA.

Senate Health Policy Holds Testimony on Opioid Legislation

The Senate Health Policy Committee held testimony on legislation related to treating patients with opioid use disorder during the week of June 16.

Collectively, Senate Bills (SB) 397405 make numerous changes to improve coverage and access for Michiganders to receive treatment for opioid use disorder. SBs 397, 400, 401, 402 and 403 specifically apply commercial insurer and Medicaid coverage modifications to reduce delays and remove additional barriers in prescribing opioid-related treatment and dosages.

SB 398 modifies opioid treatment program requirements under the Department of Licensing and Regulatory Affairs, while SBs 404405 would require nurses to carry naloxone in select schools. Lastly, SB 399 amends the Public Health Code to specify that the term “drug paraphernalia” does not include testing products.

The MHA-supported bills now await a final vote in the Senate Health Policy Committee before moving to the full Senate chamber. The MHA Behavioral Health Integration Council reviewed and recommended changes for SBs 397, 398, 399, 400 and 402.

Members with additional questions should contact the MHA Advocacy Team.